지니너스
Financials
Valuation Metrics
지니너스's Market Cap is ₩855B. At end of 2025 it was ₩1379B. Ranked #1346 of 2,436 in KR market (top 55%), #746 of 1,649 on KOSDAQ (top 45%), #145 of 234 in Pharmaceuticals, Biotechnology & Life Sciences (top 62%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 85.48B KRW | KR#1,346/2,436 Sec#145/234 |
| Revenue | 10.24B KRW | KR#2,286/2,436 Sec#177/234 |
| Net Income | -17.03B KRW | KR—/2,436 Sec—/234 |
| Total Assets | 57.45B KRW | KR#2,115/2,436 Sec#186/234 |
| Net Assets | 27.39B KRW | KR#2,189/2,436 Sec#198/234 |
| Employees | 73 | KR#1,833/2,436 Sec#156/234 |
| Value | ||
| P/B | 3.12x | KR#2,128/2,436 Sec#167/234 |
| P/S | 8.35x | KR#2,246/2,436 Sec#156/234 |
| FCF Yield | -9.84% | KR—/2,436 Sec—/234 |
| Profitability | ||
| ROE | -62.18% | KR#2,296/2,436 Sec#207/234 |
| ROA | -29.65% | KR#2,299/2,436 Sec#198/234 |
| Op. Margin | -110.71% | KR#2,315/2,436 Sec#176/234 |
| Revenue Growth | -9.23% | KR#1,846/2,436 Sec#171/234 |
| Financial Health | ||
| Debt Ratio | 109.73% | KR#433/2,436 Sec#61/234 |
| Total Debt | 8.29B KRW | KR#1,676/2,436 Sec#155/234 |
| FCF | -8.42B KRW | KR#1,660/2,436 Sec#139/234 |
| Cash | 26.95B KRW | KR#1,060/2,436 Sec#71/234 |
| Current Ratio | 1.42x | KR#1,373/2,436 Sec#147/234 |
| Performance | ||
| 1Y Return | 30.72% | KR#338/2,436 Sec#30/234 |
| 1M Return | -2.91% | KR#1,206/2,436 Sec#117/234 |
| From 52W High | -66.51% | KR#2,015/2,436 Sec#173/234 |
| 1Y MDD | -71.24% | KR#2,001/2,436 Sec#176/234 |
| Trading | ||
| Volume | 266,568 shares | KR#445/2,436 Sec#44/234 |
| Foreign Own. | 3.75% | KR#919/2,436 Sec#89/234 |
| Per Share | ||
| EPS | -509 KRW | KR—/2,436 Sec—/234 |
| BPS | 698 KRW | KR#2,351/2,436 Sec#220/234 |
Company Info
Spun off from Samsung Genome Research Institute in 2018, this bio venture specializes in genome analysis and solution development. It offers NGS-based cancer genome diagnostic solution CancerSCAN, single-cell analysis platform Celinus, and cloud-based spatial omics analysis solution SPACEINSIGHT. The company is advancing new businesses like AI-based new drug development and digital pathology-based companion diagnostic solutions, while collaborating with domestic and international pharmaceutical companies using its single-cell and spatial omics analysis technologies.